CX-4945 could be also applicable in the treatment of glioblastoma where CLK2 modulates phosphorylation of Forkhead box O3a (FOXO3a)/p27 and, consequently, cell cycle and survival of tumor cells [121]. Here, FOXO3 is linked to neoplasm.